Irbesartan Mylan

Irbesartan, the active ingredient in Irbesartan Mylan, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is used to treat hypertension and to protect kidney function in patients with diabetic nephropathy.

GNH USA supplies Irbesartan Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan belongs to the angiotensin II receptor blocker class and is employed in conditions related to the renin‑angiotensin system. - Hypertension: lowers elevated blood pressure to reduce cardiovascular strain. - Diabetic nephropathy: slows progression of kidney damage in type 2 diabetes. - Cardiovascular risk reduction: helps lower the risk of stroke and heart‑failure events in patients with high blood pressure.

Adverse reactions may occur with any medication. The following lists reported events associated with Irbesartan.

Common Side Effects: - Dizziness - Headache - Fatigue - Nausea - Diarrhea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angioedema - Hyperkalemia - Acute kidney injury - Hepatic injury - Severe hypotension - Myocardial infarction

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal function assessment: check serum creatinine and eGFR regularly. - Serum potassium: monitor for hyperkalaemia, especially with concomitant potassium‑sparing agents. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy: avoid use during pregnancy due to unknown safety. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment. - Combined ARB/ACE‑inhibitor therapy: heightened risk of hyperkalaemia and renal dysfunction. - Potassium‑sparing diuretics: may cause dangerous hyperkalaemia. - NSAIDs: can reduce renal perfusion and potentiate kidney injury. - Lithium: may raise lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: additive blood‑pressure lowering effect. - CYP2C9 inhibitors (e.g., fluconazole): may increase Irbesartan plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic efficacy.